PTC Therapeutics, Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
PTC Therapeutics, Inc. (PTCT) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $1.14 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $1.14B.
- 2026-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $988.54M.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $929.13M.
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $971.24M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $1.14B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $988.54M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $929.13M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $971.24M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $937.56M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $518.76M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $330.95M 10-K · filed 2026-02-19 |
| 2024-09-30 | $458.10M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $421.63M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $306.08M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $260.10M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.63M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $1.60M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $10.25M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $12.42M 10-K · filed 2024-02-29 |
| 2022-09-30 | $36.22M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $86.89M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $111.44M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $221.61M 10-K · filed 2023-02-21 |
| 2021-09-30 | $322.47M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $410.55M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $450.92M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $588.86M 10-K · filed 2022-02-22 |
| 2020-09-30 | $574.55M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $255.59M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $380.31M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $342.42M 10-K · filed 2021-02-25 |
| 2019-09-30 | $127.89M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $161.13M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $144.88M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $58.09M 10-K · filed 2020-03-02 |
| 2018-09-30 | $42.49M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $72.32M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $80.59M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $69.38M 10-K · filed 2019-03-01 |
| 2017-09-30 | $27.47M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $48.06M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $144.48M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $157.35M 10-K · filed 2018-03-06 |
| 2016-09-30 | $163.94M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $186.06M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $195.02M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $186.78M 10-K · filed 2017-03-16 |
| 2015-09-30 | $164.12M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $166.75M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $169.39M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $163.76M 10-K · filed 2016-02-29 |
| 2014-09-30 | $65.86M 10-Q · filed 2014-11-06 |
| 2013-12-31 | $69.16M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |